Top-Rated StocksTop-RatedNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $133.75 -0.63 (-0.47%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$132.99▼$136.3650-Day Range$121.07▼$140.8052-Week Range$85.29▼$161.00Volume175,736 shsAverage Volume368,193 shsMarket Capitalization$7.79 billionP/E RatioN/ADividend YieldN/APrice Target$179.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Ascendis Pharma A/S alerts: Email Address Ascendis Pharma A/S MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside33.8% Upside$179.00 Price TargetShort InterestBearish5.92% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.14Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.53) to ($1.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.46 out of 5 starsMedical Sector309th out of 936 stocksPharmaceutical Preparations Industry144th out of 436 stocks 4.5 Analyst's Opinion Consensus RatingAscendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.92% of the outstanding shares of Ascendis Pharma A/S have been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 2.54%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASND. Previous Next 4.0 News and Social Media Coverage News SentimentAscendis Pharma A/S has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Ascendis Pharma A/S this week, compared to 4 articles on an average week.Search Interest5 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows1 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ascendis Pharma A/S's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($5.53) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -13.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -13.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ascendis Pharma A/S's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Ascendis Pharma A/S Stock (NASDAQ:ASND)Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Read More ASND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASND Stock News HeadlinesJuly 26 at 2:52 AM | americanbankingnews.comCantor Fitzgerald Brokers Raise Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND)July 24 at 2:46 PM | finance.yahoo.comDespite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 yearJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.July 21, 2024 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Receives $179.00 Consensus Target Price from BrokeragesJune 24, 2024 | globenewswire.comData from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024June 4, 2024 | globenewswire.comAscendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 3, 2024 | globenewswire.comAscendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024May 30, 2024 | globenewswire.comAscendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 17, 2024 | nasdaq.comAugust 16th Options Now Available For Ascendis Pharma (ASND)May 16, 2024 | markets.businessinsider.comAnalyst Issues ‘Buy’ Rating on Ascendis Pharma, Anticipates FDA Approval for TransCon PTHMay 15, 2024 | markets.businessinsider.comPositive Outlook on Ascendis Pharma with Buy Rating Amid Expected US Approval of TransCon PTHMay 15, 2024 | finance.yahoo.comFDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three MonthsMay 15, 2024 | stockhouse.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon(TM) PTH for Adults with HypoparathyroidismMay 14, 2024 | finance.yahoo.comUPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapyMay 14, 2024 | finance.yahoo.comUS Equity Markets Close Higher Tuesday as Producer Prices RiseMay 14, 2024 | reuters.comFDA extends review of Ascendis Pharma's hormone disorder therapyMay 14, 2024 | globenewswire.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismSee More Headlines Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Estimated)9/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ASND CUSIPN/A CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees879Year FoundedN/APrice Target and Rating Average Stock Price Target$179.00 High Stock Price Target$262.00 Low Stock Price Target$113.00 Potential Upside/Downside+33.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($9.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-521,070,000.00 Net Margins-152.68% Pretax Margin-150.57% Return on Equity-16,574.15% Return on Assets-60.06% Debt Debt-to-Equity RatioN/A Current Ratio0.83 Quick Ratio0.54 Sales & Book Value Annual Sales$288.08 million Price / Sales27.04 Cash FlowN/A Price / Cash FlowN/A Book Value($2.73) per share Price / Book-48.99Miscellaneous Outstanding Shares58,230,000Free Float34,939,000Market Cap$7.79 billion OptionableOptionable Beta0.63 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jan Moller Mikkelsen (Age 64)President, CEO, Member of Executive Board & Executive Director Mr. Scott T. Smith (Age 50)CFO, Executive VP & Member of Executive Board Ms. Lotte Sonderbjerg (Age 63)Executive VP, Chief Administrative Officer & Member of the Executive Board Mr. Michael Wolff Jensen L.L.M. (Age 53)Executive VP, Chief Legal Officer & Member of the Executive Board Mr. Mads BodenhoffSenior VP of Finance & Principal Accounting OfficerMr. Timothy J. LeeSenior Director of Investor RelationsMr. Flemming Steen Jensen (Age 63)Executive Vice President of Product Supply & Quality Dr. Kennett Sprogoe Ph.D. (Age 45)Executive VP and Head of Research & Product Development Dr. Stina Singel M.D. (Age 50)Ph.D., Executive VP & Head of Clinical Development for Oncology Mr. Joseph Kelly (Age 55)Head of U.S. Commercial of Endocrinology More ExecutivesKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYTeva Pharmaceutical IndustriesNYSE:TEVAGenmab A/SNASDAQ:GMABRoyalty PharmaNASDAQ:RPRXBioMarin PharmaceuticalNASDAQ:BMRNView All CompetitorsInstitutional OwnershipAllspring Global Investments Holdings LLCSold 9,956 shares on 7/26/2024Ownership: 0.308%Bank of New York Mellon CorpSold 40,303 shares on 7/26/2024Ownership: 0.190%Legato Capital Management LLCBought 2,708 shares on 7/26/2024Ownership: 0.007%Baillie Gifford & Co.Sold 10,135 shares on 7/25/2024Ownership: 0.122%China Universal Asset Management Co. Ltd.Sold 4,216 shares on 7/20/2024Ownership: 0.012%View All Institutional Transactions ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $125.95 at the beginning of the year. Since then, ASND shares have increased by 6.2% and is now trading at $133.75. View the best growth stocks for 2024 here. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Thursday, May, 2nd. The biotechnology company reported ($2.48) EPS for the quarter, missing the consensus estimate of ($1.57) by $0.91. The biotechnology company earned $103.11 million during the quarter, compared to the consensus estimate of $85.72 million. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative trailing twelve-month return on equity of 16,574.15%. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Top institutional investors of Ascendis Pharma A/S include ARS Investment Partners LLC (0.43%), Allspring Global Investments Holdings LLC (0.31%), Bank of New York Mellon Corp (0.19%) and Baillie Gifford & Co. (0.12%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD) and Incyte (INCY). This page (NASDAQ:ASND) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
